$3.98 $0.19 (0.0%)

04:00 PM EDT on 06/25/19

Adaptimmune Therapeutics plc (NASDAQ:ADAP)

CAPS Rating: 3 out of 5

Current Price $3.98 Mkt Cap $396.9M
Open $3.81 P/E Ratio 0.00
Prev. Close $3.98 Div. (Yield) $0.00 (0.0%)
Daily Range $3.77 - $4.01 Volume 53,218
52-Wk Range $3.20 - $6.30 Avg. Daily Vol. 7

Caps

How do you think NASDAQ:ADAP will perform against the market?

Add Stock to CAPS Watchlist

All Players

38 Outperform
2 Underperform
 

All-Star Players

16 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:ADAP Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.77)
Submitted May 14, 2015

Adaptimmune is another addition for zzporte's basket of CAR-T/affinity-enhanced TCR immunotherapy stocks that already includes Juno, Kite, and Bellicum in the US and others in Europe. I don't think we have any enormous insight into this recent IPO,… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:ADAP VS S&P 500 (SPY)

NASDAQ:ADAP Summary

Fools bullish on NASDAQ:ADAP are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about ADAP.

Recs

0
Member Avatar Bigsef77 (68.18) Submitted: 4/3/2019 11:04:50 AM : Outperform Start Price: $13.05 NASDAQ:ADAP Score: -79.59

Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) Meeting
GlobeNewswire•April 2, 2019

PHILADELPHIA and OXFORD, United Kingdom, April 02, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (ADAP), a leader in T-cell therapy to treat cancer, presented initial safety data from two patients with advanced hepatocellular carcinoma (HCC), liver cancer, from the first dose cohort of the ADP-A2AFP study at the annual AACR meeting.

“We did not observe clinically significant liver toxicity in the two patients treated at a dose of 100 million transduced cells, and these data supported dose escalation to the second cohort. Even though data are preliminary, we are encouraged by the evidence of tumor necrosis we saw in one of the two patients. We have started dosing patients with higher cell doses and there continues to be no evidence of hepatotoxicity or other dose limiting toxicities. We will give an update on this study as well as our other ongoing trials during our May quarterly call,” said Rafael Amado, Adaptimmune’s President of Research & Development.

There was no evidence of clinically significant hepatotoxicity, off-target toxicity, or alloreactivity, and no protocol-defined dose limiting toxicities were observed. Most adverse events were consistent with those typically experienced by cancer patients undergoing cytotoxic chemotherapy or other cancer immunotherapies.

Imaging and a post-treatment biopsy for one patient showed evidence of tumor necrosis with lymphocytic infiltration, concurrent with a transient decrease in serum AFP. In addition, ADP-A2AFP SPEAR T-cells were detectable in the peripheral blood. The patient later progressed at Week 16.

Based on these initial safety data, the Safety Review Co

Recs

0
Member Avatar Hendrickson71 (< 20) Submitted: 10/21/2015 4:29:46 PM : Outperform Start Price: $9.00 NASDAQ:ADAP Score: -99.09

Different from the other T-CARs next year expanding away from oncology into other areas.....this is no one trick pony.

Recs

0
Member Avatar StockMarketKid13 (67.97) Submitted: 6/21/2015 8:22:23 PM : Outperform Start Price: $19.27 NASDAQ:ADAP Score: -118.77

good

Leaderboard

Find the members with the highest scoring picks in ADAP.

Score Leader

sln

sln (69.47) Score: +111.77

The Score Leader is the player with the highest score across all their picks in ADAP.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
svenof 29.84 12/1/2015 Underperform 5Y $9.26 -57.02% +38.62% +95.64 0 Comment
capstrarian 91.62 1/29/2019 Underperform 5Y $4.67 -14.78% +10.40% +25.17 0 Comment
flypower 98.71 11/29/2016 Outperform 5Y $4.40 -9.55% +31.51% -41.05 0 Comment
NextGenStock < 20 11/8/2018 Outperform 5Y $6.61 -39.79% +3.55% -43.33 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. trackjakeambrose 70.28 11/7/2016 Outperform 5Y $4.30 -7.44% +36.70% -44.14 0 Comment
jeepdrew222 69.09 7/14/2017 Outperform 5Y $5.36 -25.75% +19.01% -44.76 0 Comment
acekeldog 99.65 10/22/2018 Outperform 3M $7.84 -49.23% +5.62% -54.85 0 Comment
ak1010 99.84 2/7/2018 Outperform 5Y $8.50 -53.18% +8.34% -61.52 0 Comment
portefeuille6 99.48 9/2/2016 Outperform 5Y $6.58 -39.51% +33.37% -72.88 0 Comment
portefeuille4 99.47 9/2/2016 Outperform 5Y $6.60 -39.68% +33.39% -73.07 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ADAP.

Advertisement